Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMLTI39)

Drug Name
Lumiliximab Drug Info
Synonyms Gomiliximab; IDEC-152; SI-3401; ST-152; PRIMATIZED anti-CD23 antibody, IDEC
Indication
Disease Entry ICD 11 Status REF
leukaemia 2A60-2B33 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMLTI39

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lymphocyte IgE receptor (CD23) TTCH6MU FCER2_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Lymphocyte IgE receptor (CD23) DTT FCER2 2.485 1.263 1.07 2.307
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease leukaemia
ICD Disease Classification 2A60-2B33
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Lymphocyte IgE receptor (CD23) DTT FCER2 9.88E-01 -0.1 -0.23
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00391066) Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL). U.S. National Institutes of Health.
2 Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol. 2005 Oct;116(4):780-8.